HC Wainwright Issues Pessimistic Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.17) for the year, down from their prior estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.04) EPS and FY2028 earnings at $1.58 EPS.

Separately, Craig Hallum boosted their price target on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $12.74 on Thursday. The business has a 50-day simple moving average of $8.23 and a 200-day simple moving average of $5.36. The company has a market cap of $329.15 million, a PE ratio of -56.05 and a beta of 1.25. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $12.77.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. acquired 16,852 shares of the stock in a transaction dated Friday, October 4th. The stock was bought at an average cost of $6.77 per share, with a total value of $114,088.04. Following the purchase, the insider now directly owns 2,720,000 shares of the company’s stock, valued at approximately $18,414,400. This represents a 0.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have acquired 85,600 shares of company stock valued at $462,674. Insiders own 14.89% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently made changes to their positions in the business. Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth about $3,095,000. Westside Investment Management Inc. raised its holdings in shares of Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after buying an additional 33,275 shares during the period. Geode Capital Management LLC lifted its position in Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after acquiring an additional 32,365 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares in the last quarter. Finally, Wasatch Advisors LP purchased a new position in Eton Pharmaceuticals in the 3rd quarter worth approximately $1,431,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.